<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Odent J</submitter><funding>French Community of Belgium</funding><funding>European Commission</funding><funding>European Regions Research and Innovation Network</funding><pagination>2502</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11398034</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(17)</volume><pubmed_abstract>Diabetes is a major health concern that the next-generation of on-demand insulin releasing implants may overcome via personalized therapy. Therein, 3D-printed phenylboronic acid-containing implants with on-demand glucose-triggered drug release abilities are produced using high resolution stereolithography technology. To that end, the methacrylation of phenylboronic acid is targeted following a two-step reaction. The resulting photocurable phenylboronic acid derivative is accordingly incorporated within bioinert polyhydroxyethyl methacrylate-based hydrogels at varying loadings. The end result is a sub-centimeter scaled 3D-printed bioinert implant that can be remotely activated with 1,2-diols and 1,3-diols such as glucose for on-demand drug administration such as insulin. As a proof of conce</pubmed_abstract><journal>Polymers</journal><pubmed_title>3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release.</pubmed_title><pmcid>PMC11398034</pmcid><funding_grant_id>NA</funding_grant_id><funding_grant_id>3D4MED</funding_grant_id><pubmed_authors>Raquez JM</pubmed_authors><pubmed_authors>Torcasio SM</pubmed_authors><pubmed_authors>Odent J</pubmed_authors><pubmed_authors>Coulembier O</pubmed_authors><pubmed_authors>Baleine N</pubmed_authors><pubmed_authors>Gautier S</pubmed_authors></additional><is_claimable>false</is_claimable><name>3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release.</name><description>Diabetes is a major health concern that the next-generation of on-demand insulin releasing implants may overcome via personalized therapy. Therein, 3D-printed phenylboronic acid-containing implants with on-demand glucose-triggered drug release abilities are produced using high resolution stereolithography technology. To that end, the methacrylation of phenylboronic acid is targeted following a two-step reaction. The resulting photocurable phenylboronic acid derivative is accordingly incorporated within bioinert polyhydroxyethyl methacrylate-based hydrogels at varying loadings. The end result is a sub-centimeter scaled 3D-printed bioinert implant that can be remotely activated with 1,2-diols and 1,3-diols such as glucose for on-demand drug administration such as insulin. As a proof of conce</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2025-04-19T19:28:51.845Z</modification><creation>2025-04-19T19:28:51.845Z</creation></dates><accession>S-EPMC11398034</accession><cross_references><pubmed>39274135</pubmed><doi>10.3390/polym16172502</doi></cross_references></HashMap>